Activation of the retinoid X receptor modulates angiotensin II-induced smooth muscle gene expression and inflammation in vascular smooth muscle cells

Molecular Pharmacology

Volumn 86, Issue 5, 2014, Pages 570-579

  Lehman, Allison M B ^a   Montford, John R ^a   Horita, Henrick ^a   Ostriker, Allison C ^a   Weiser Evans, Mary C M ^a,b   Nemenoff, Raphael A ^a,b   Furgeson, Seth B ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALITRETINOIN; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; BEXAROTENE; CALPONIN; DIMETHYL SULFOXIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN KINASE B; RETINOID X RECEPTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ACTIN; ACTIN BINDING PROTEIN; CALCIUM BINDING PROTEIN; CCL2 PROTEIN, RAT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TETRALIN DERIVATIVE;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL DIFFERENTIATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; INFLAMMATION; LUCIFERASE ASSAY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CELL CULTURE; DRUG EFFECTS; GENETICS; MALE; METABOLISM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ACTINS; ANGIOTENSIN II; ANIMALS; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; CHEMOKINE CCL2; GENE EXPRESSION; INFLAMMATION; MALE; MAP KINASE SIGNALING SYSTEM; MICROFILAMENT PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RETINOID X RECEPTORS; SIGNAL TRANSDUCTION; TETRAHYDRONAPHTHALENES;

EID: 84922292271     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.092163     Document Type: Article

References (38)

1. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, and Gronemeyer H (2007) RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6:793-810.
2. Auger-Messier M, Accornero F, Goonasekera SA, Bueno OF, Lorenz JN, van Berlo JH, Willette RN, and Molkentin JD (2013) Unrestrained p38 MAPK activation in Dusp1/4 double-null mice induces cardiomyopathy. Circ Res 112:48-56.
3. Benkirane K, Amiri F, Diep QN, El Mabrouk M, and Schiffrin EL (2006) PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 290:H390-H397.
4. Boergesen M, Pedersen TA, Gross B, van Heeringen SJ, Hagenbeek D, Bindesbøll C, Caron S, Lalloyer F, Steffensen KR, and Nebb HI et al. (2012) Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor α in mouse liver reveals extensive sharing of binding sites. Mol Cell Biol 32:852-867.
5. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, and James MJ et al. (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335:1503-1506.
6. Ebrahimian T, Li MW, Lemarié CA, Simeone SM, Pagano PJ, Gaestel M, Paradis P, Wassmann S, and Schiffrin EL (2011) Mitogen-activated protein kinase-activated protein kinase 2 in angiotensin II-induced inflammation and hypertension: regulation of oxidative stress. Hypertension 57:245-254.
7. Forman BM, Chen J, and Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94:4312-4317.
8. Furgeson SB, Simpson PA, Park I, Vanputten V, Horita H, Kontos CD, Nemenoff RA, and Weiser-Evans MC (2010) Inactivation of the tumour suppressor, PTEN, in smooth muscle promotes a pro-inflammatory phenotype and enhances neointima formation. Cardiovasc Res 86:274-282.
9. Garat C, Van Putten V, Refaat ZA, Dessev C, Han SY, and Nemenoff RA (2000) Induction of smooth muscle alpha-actin in vascular smooth muscle cells by arginine vasopressin is mediated by c-Jun amino-terminal kinases and p38 mitogenactivated protein kinase. J Biol Chem 275:22537-22543.
10. Heeneman S, Sluimer JC, and Daemen MJ (2007) Angiotensin-converting enzyme and vascular remodeling. Circ Res 101:441-454.
11. Horita HN, Simpson PA, Ostriker A, Furgeson S, Van Putten V, Weiser-Evans MC, and Nemenoff RA (2011) Serum response factor regulates expression of phosphatase and tensin homolog through a microRNA network in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 31:2909-2919.
12. Imayama I, Ichiki T, Patton D, Inanaga K, Miyazaki R, Ohtsubo H, Tian Q, Yano K, and Sunagawa K (2008) Liver X receptor activator downregulates angiotensin II type 1 receptor expression through dephosphorylation of Sp1. Hypertension 51:1631-1636.
13. Ishizawa M, Kagechika H, and Makishima M (2012) NR4A nuclear receptors mediate carnitine palmitoyltransferase 1A gene expression by the rexinoid HX600. Biochem Biophys Res Commun 418:780-785.
14. Kim HJ, Ham SA, Kim MY, Hwang JS, Lee H, Kang ES, Yoo T, Woo IS, Yabe-Nishimura C, and Paek KS et al. (2011) PPARδ coordinates angiotensin II-induced senescence in vascular smooth muscle cells through PTEN-mediated inhibition of superoxide generation. J Biol Chem 286:44585-44593.
15. Lalloyer F, Fiévet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, and Paumelle R et al. (2006) The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 26:2731-2737.
16. Lalloyer F, Pedersen TA, Gross B, Lestavel S, Yous S, Vallez E, Gustafsson JA, Mandrup S, Fiévet C, and Staels B et al. (2009) Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver. Arterioscler Thromb Vasc Biol 29:1488-1495.
17. Lansigan F and Foss FM (2010) Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 70:273-286.
18. Lawrence JA, Adamson PC, Caruso R, Chow C, Kleiner D, Murphy RF, Venzon DJ, Shovlin M, Noone M, and Merino M et al. (2001) Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. J Clin Oncol 19:2754-2763.
19. Lefebvre P, Benomar Y, and Staels B (2010) Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab 21:676-683.
20. Mack CP (2011) Signaling mechanisms that regulate smooth muscle cell differentiation. Arterioscler Thromb Vasc Biol 31:1495-1505.
21. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, and Dominiczak A et al. (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34:2159-2219.
22. Mehta PK and Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292:C82-C97.
23. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, and Nadzan AM et al. (1997) Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386:407-410.
24. Nemenoff RA, Simpson PA, Furgeson SB, Kaplan-Albuquerque N, Crossno J, Garl PJ, Cooper J, and Weiser-Evans MC (2008) Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1alpha. Circ Res 102:1036-1045.
25. Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, Hoffmann A, Subramaniam S, David M, and Rosenfeld MG et al. (2005) Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122:707-721.
26. Oliver WR, Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, and Lambert MH et al. (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306-5311.
27. Owens GK, Kumar MS, and Wamhoff BR (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84:767-801.
28. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, and Willson TM (2002) 6α-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 45:3569-3572.
29. Pettersson F, Hanna N, Lagodich M, Dupéré-Richer D, Couture MC, Choi C, and Miller WH, Jr (2008) Rexinoids modulate steroid and xenobiotic receptor activity by increasing its protein turnover in a calpain-dependent manner. J Biol Chem 283:21945-21952.
30. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, and Mangelsdorf DJ (2000) Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289:1524-1529.
31. Richter MH, Richter HR, Olbrich HG, and Mohr FW (2003) Two good reasons for an angiotensin-II type 1 receptor blockade with losartan after cardiac transplantation: reduction of incidence and severity of transplant vasculopathy. Transpl Int 16:26-32.
32. Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, Gill GM, Ulm EH, Geiser R, and Jaunakais D et al. (1999) A phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 5:1658-1664.
33. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, and Sawada H (2000) Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278:704-711.
34. Sanz MJ, Albertos F, Otero E, Juez M, Morcillo EJ, and Piqueras L (2012) Retinoid X receptor agonists impair arterial mononuclear cell recruitment through peroxisome proliferator-activated receptor-g activation. J Immunol 189:411-424.
35. Széles L, Póliska S, Nagy G, Szatmari I, Szanto A, Pap A, Lindstedt M, Santegoets SJ, Rühl R, and Dezsö B et al. (2010) Research resource: transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells. Mol Endocrinol 24:2218-2231.
36. Takahashi M, Suzuki E, Takeda R, Oba S, Nishimatsu H, Kimura K, Nagano T, Nagai R, and Hirata Y (2008) Angiotensin II and tumor necrosis factor-alpha synergistically promote monocyte chemoattractant protein-1 expression: roles of NF-κB, p38, and reactive oxygen species. Am J Physiol Heart Circ Physiol 294:H2879-H2888.
37. Tanaka T, Suh KS, Lo AM, and De Luca LM (2007) p21WAF1/CIP1 is a common transcriptional target of retinoid receptors: pleiotropic regulatory mechanism through retinoic acid receptor (RAR)/retinoid X receptor (RXR) heterodimer and RXR/RXR homodimer. J Biol Chem 282:29987-29997.
38. Valente AJ, Yoshida T, Murthy SN, Sakamuri SS, Katsuyama M, Clark RA, Delafontaine P, and Chandrasekar B (2012) Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am J Physiol Heart Circ Physiol 303:H282-H296.